Detalles de la búsqueda
1.
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med
; 389(21): 1961-1971, 2023 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37870920
2.
Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
World J Urol
; 41(12): 3413-3420, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37698632
3.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 612-624, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35390339
4.
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Int J Cancer
; 151(8): 1335-1344, 2022 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35603906
5.
BAG6 promotes PINK1 signaling pathway and is essential for mitophagy.
FASEB J
; 35(2): e21361, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33522017
6.
PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
World J Urol
; 39(11): 4055-4065, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32666225
7.
Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study.
BMC Cancer
; 20(1): 757, 2020 Aug 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32787797
8.
Feasibility and efficacy of a supervised home-based physical exercise program for metastatic cancer patients receiving oral targeted therapy: study protocol for the phase II/III - UNICANCER SdS 01 QUALIOR trial.
BMC Cancer
; 20(1): 975, 2020 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33036567
9.
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Lancet Oncol
; 25(5): 531-533, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38621399
10.
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
BMC Cancer
; 18(1): 194, 2018 02 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-29454321
11.
Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
World J Urol
; 36(11): 1727-1740, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29855698
12.
Ductal adenocarcinoma of the prostate: Clinical and biological profiles.
Prostate
; 77(12): 1242-1250, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28699202
13.
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma.
BJU Int
; 117(3): 444-9, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25601543
14.
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 16(4): 417-25, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25743937
15.
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Lancet Oncol
; 16(7): 787-94, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26028518
16.
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
BMC Cancer
; 15: 222, 2015 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-25884302
17.
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
BJU Int
; 115(1): 65-73, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24180479
18.
Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study.
BJU Int
; 115(1): 87-93, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24825727
19.
Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients.
J Negat Results Biomed
; 14: 18, 2015 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26555878
20.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(7): 700-12, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24831977